EARLY Labs

Excited and proud to share our peer-reviewed publication in a special edition of the Journal of Clinical Medicine on the topic of Clinical Research Advances in Thoracic Surgery. The paper details a joint study led by Professor Ory Wiesel, MD from the Tzafon Medical Center outlining 5 real world patient cases demonstrating clear benefits of using EARLY's lung cancer early detection urine test as a decision support tool to the existing lung cancer diagnostic and treatment pathways. Michal Mark Danieli, PhD Adi Laser, Tanya Suharev, Neal Navani, David M. Knapp, Ph.D., Elad Duschak

In a perfect world all lung cancer patients would receive best-practice care, but unfortunately this is not the case. Providing wide access to lung cancer screening can help address disparities in lung cancer care, take a look at this important article by the Lung Cancer Policy Network https://lnkd.in/dMHMiR_s

World lung day is a great opportunity to reflect on what we can all do to keep our air cleaner, and take better care of our lungs. Lung cancer cases among non smokers is on a continues rise, and air pollution is a major factor. https://lnkd.in/gbbsCNv9

Although smoking prevalence among men in India is one of the highest in the world - most lung cancer patients in India never smoked! Lung cancer among never-smokers, women in particular, is on a continues rise globally, and the affect of air pollution and other environmental factors as well as genetic predisposition are becoming increasingly recognized as leading contributors. Current western lung cancer screening programs include only heavy smokers, is it time to reconsider these policies? It is time - time for a simple and non-invasive pre-screening test that can be sampled at the comfort of home, and will be available to a wider population. Time to start EARLY https://lnkd.in/dZpfrYup

We are super excited and proud to announce two significant additions to our advisory board at Early Labs. Please join us in welcoming David M. Knapp PhD, and Neal Navani M.B.B.S to our team. Welcoming David M. Knapp, PhD: David M. Knapp is an international R&D leader in medical device and technology innovation, development, and exploratory research. In his 24 years at Boston Scientific, as VP R&D David led the PI and Vascular R&D portfolio and gained extensive experience in driving all aspects of product and technology development end-to-end. David Knapp is a board member of several research institutes and life science companies, and is a regular speaker and panelist in world leading MedTech conferences and conventions. We are confident that David's deep knowledge and strategic insights will be instrumental in guiding Early Labs to new heights. Welcoming Neal Navani M.B.B.S.: Neal Navani  A world class key opinion leader in the realm of lung cancer research and treatment.  Lead clinician for the lung cancer services at UCLH, senior clinical lead of the UK National Lung Cancer Audit , Respiratory representative on the NICE lung cancer guideline. Chairs the lung cancer board for the North Central and East London Cancer Alliance. His recent MRC/NIHR fellowship highlights his dedication to advancing cancer research with novel predictors for lung nodules. Neals' vast experience and commitment to advancing lung cancer patient care will be crucial as we strive to drive innovation forward at Early Labs. We are confident that David's and Neal's leadership and expertise will significantly advance our mission and propel us forward! Stay tuned for more updates. 

The incidence of lung cancer in women is increasing, specifically for non-smokers. This important article highlights potential factors like environmental exposures and genetic predispositions, and the urgent need for increased research and awareness to address this growing issue effectively. Early Labs is dedicated to advancing medical research and supporting initiatives that promote lung cancer awareness and enhance women’s health. #EarlyLabs #LungCancerAwareness #WomenInHealth  https://lnkd.in/e5XWfhfT

https://lnkd.in/dwed_sXh Interesting piece by "Sensitive & Specific: The Testing Newsletter", With maturity of machine learning algorithms and access to massive computing power we can now analyze complex biological patterns based on rats sense of smell to explore new frontiers in non-invasive early cancer detection. Harnessing the power of nature to solve one of humanities biggest challenges - makes perfect sense

https://lnkd.in/diZdn3VY Despite massive efforts to increase adoption, the vast majority of U.S. eligible population do not undergo lung cancer screening using Low Dose CT. Long queues, the overall test time, low availability in rural areas, uncomfortable patient journey and radiation exposure - are factors which are tough to tackle.  A urine test for lung cancer risk assessment, sampled in 3 minutes at the comfort of home - has the potential to completely change this paradigm.

We were honored to be a part of this important Biomed Israel 2024 session on early detection, showcasing fascinating technologies and case studies. One key takeaway - developing an effective, non-invasive, early detection cancer screening test remains a major unmet challenge (but hopefully not for long.....). Thank you Yaron Daniely and Ofer Sharon for gracefully hosting, and a huge thumbs up to Ruti Alon for setting up this amazing conference in such difficult times!